EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population

Li Zhou iD, Zhiting Shao, Yiqiang Liu, Xieqiao Yan, Juan Li, Xiaowen Wu, Bixia Tang, Siming Li, Chuanliang Cui, Zhihong Chi, Lu Si, Yan Kong und 7 weitere

The Oncologist · 03.08.2023 · 28 (8) · e617-e624

DOI: 10.1093/oncolo/oyad070 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Oncologist, online erschienen am 27.03.2023. Verfasst von Li Zhou und 18 weiteren Autor:innen. Beteiligte Einrichtung: Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University …. Hauptthemen laut MEDLINE: Carcinoma, Transitional Cell, Urinary Bladder Neoplasms. Die Arbeit wurde bisher 39-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: National Natural Science Foundation of China, Science Foundation of Peking University Cancer Hospital, Beijing Xisike Clinical Oncology Research Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The frequency of HER2 overexpression in bladder cancer is reported as 9%-61%. HER2 alteration correlates with aggressive disease in bladder cancer. Traditional anti-HER2 targeted therapy has failed to show clinical benefits in patients with advanced urothelial carcinoma .

Methods

The information on pathologically proven patients with urothelial carcinoma with detected HER2 status was collected from the database of Peking University Cancer Hospital. The HER2 expression, as well as its association with clinical characteristics and prognosis, was analyzed.

Results

A total of 284 consecutive patients with urothelial carcinoma were enrolled. HER2 was positive (IHC 2+/3+) in 44% of urothelial carcinoma. HER2 positivity was found more frequent in UCB than in UTUC (51% vs. 38%). Stage, radical surgery, and histological variant were associated with survival (P < .05). For metastatic patients, multivariate analysis shows that 3 indicators, including liver metastasis, the number of involved organs, and anemia, are independent risk factors of prognosis. Receiving immunotherapy or disitamab vedotin (DV) treatment is an independent protecting factor. The survival of patients with low HER2 expression was also significantly improved by the treatment of DV (P < .001). HER2 expression (IHC 1+, 2+, 3+) was associated with a better prognosis in this population.

Conclusion

DV has improved the survival of patients with urothelial carcinoma in the real world. With the new-generation anti-HER2 ADC treatment, HER2 expression is no longer a poor prognostic factor.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Transitional CellUrinary Bladder NeoplasmsHumansEast Asian PeoplePrognosisAntibodies, MonoclonalOligopeptidesErb-b2 Receptor Tyrosine Kinases

Stichwörter der Autor:innen

HER2antibody-drug conjugateprognosistargeted therapyurothelial carcinoma

Substanzen

disitamab vedotinAntibodies, MonoclonalOligopeptidesERBB2 protein, humanErb-b2 Receptor Tyrosine Kinases

Autor:innen und Institutionen

  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Genitourinary Oncology, Peking University Cancer Hospital & Institute, Beijing, People's Republic of China.
  • Department of Hematology, Oncology, and Tumor Immunology, Charité-Universitätsmedizin Berlin, Berlin, Germany.
  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Pathology, Peking University Cancer Hospital & Institute, Beijing, People's Republic of China.
  • Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education/Beijing), Department of Melanoma and Sarcoma, Peking University Cancer Hospital & Institute, Beijing, People's Republic of China.

ORCID-Profile: Li Zhou, Xue Bai, Xinan Sheng

Förderung

  • National Natural Science Foundation of China
  • Science Foundation of Peking University Cancer Hospital
  • Beijing Xisike Clinical Oncology Research Foundation

Zitieren

APA

Zhou, L., Shao, Z., Liu, Y., Yan, X., Li, J., Wu, X., Tang, B., Li, S., Cui, C., Chi, Z., Si, L., Kong, Y., Mao, L., Lian, B., Wang, X., Bai, X., Dai, J., Guo, J., & Sheng, X. (2023). HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population. The Oncologist, 28(8), e617-e624. https://doi.org/10.1093/oncolo/oyad070

Vancouver

Zhou L, Shao Z, Liu Y, Yan X, Li J, Wu X, et al. HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population. The Oncologist. 2023;28(8):e617-e624. doi:10.1093/oncolo/oyad070

BibTeX
@article{Zhou2023,
  author = {Zhou, Li and Shao, Zhiting and Liu, Yiqiang and Yan, Xieqiao and Li, Juan and Wu, Xiaowen and Tang, Bixia and Li, Siming and Cui, Chuanliang and Chi, Zhihong and Si, Lu and Kong, Yan and Mao, Lili and Lian, Bin and Wang, Xuan and Bai, Xue and Dai, Jie and Guo, Jun and Sheng, Xinan},
  title = {HER2 Expression Associated with Clinical Characteristics and Prognosis of Urothelial Carcinoma in a Chinese Population},
  journal = {The Oncologist},
  year = {2023},
  volume = {28},
  number = {8},
  pages = {e617--e624},
  doi = {10.1093/oncolo/oyad070}
}
Kostenlos starten →